Inflammatory Process Modulation by Homeopathic Arnica montana 6CH: The Role of Individual Variation

Table 5

General view of results obtained in rats that developed spontaneous peak of oedema between 0 and 30 minutes (early oedema subgroup) after the injection of 1% carrageenan into the footpad. *Kruskal-Wallis, 𝑃≤.05; ^#𝑋², 𝑃=.0001 in relation to control. ^##ANOVA, Tuckey-Krammer, 𝑃≤.05 in relation to the late oedema subgroup (Table 6).

Early oedema subgroup	Control (vehicle)	Arnica montana 6cH	Dexamethasone (4 mg/kg)
Paw oedema (180 min)	0.63±0.45^a	0.78±0.54^##	0.89±0.48^##
Degranulated mast cells	14%	20%^#	16%
Lymphatic vessels diameter	101.12±45.25^b	108.08±84.33	105.95±63.06
CD 54	2 (2–6)^c	5 (3–8)*	4 (3–6)
PMN	158.11±29.88^d	172.30±21.60	175.90±32.52
CD45RA	23.5±35.34	26.33±16.37	26.25±13.79
CD18	62.11±24.63	52.11±17.87	72.88±21.58
CD163	37.28±6.42	33.22±9.56	32.66±8.12
MAC 387	46.87±7.82	48.8±10.11	50.9±8.84
CD3	11.11±4.04	13.8±9.39	12.2±4.13
CD163/MAC387 ratio	0.51	0.56	0.60

^amean ± standard deviation; millimeters.
^bmean ± standard deviation; pixels per field.
^cmedian and interval; scores attributed by two independent observers.
^dmean ± standard deviation; cells per field.